Tumor response | No PVTT | P | PVTT types I, II, III and IV | P | ||
---|---|---|---|---|---|---|
Sorafenib group (n = 19) | TACE + sorafenib group (n = 24) | Sorafenib group (n = 21) | TACE + sorafenib group (n = 24) | |||
CR, n (%) | 2 (10.53%) | 3 (12.5%) | 1.000 | 0 (0%) | 0 (0%) | - |
PR, n (%) | 2 (10.53%) | 2 (8.33%) | 1.000 | 1 (4.76%) | 4 (16.67%) | 0.352 |
SD, n (%) | 10 (52.63%) | 8 (33.33%) | 0.203 | 8 (38.1%) | 10 (41.67%) | 0.807 |
PD, n (%) | 5 (26.32%) | 11 (45.83%) | 0.189 | 12 (57.14%) | 10 (41.67%) | 0.300 |
OR, n (%) | 4 (21.06%) | 5 (20.83%) | 1.000 | 1 (4.76%) | 4 (16.67%) | 0.352 |